USP44 Antikörper (Internal Region)
Kurzübersicht für USP44 Antikörper (Internal Region) (ABIN6258564)
Target
Alle USP44 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- Internal Region
-
Spezifität
- USP44 Antibody detects endogenous levels of total USP44.
-
Homologie
- Bovine,Horse,Sheep,Dog
-
Aufreinigung
- The antiserum was purified by peptide affinity chromatography using SulfoLinkTM Coupling Resin (Thermo Fisher Scientific).
-
Immunogen
- A synthesized peptide derived from human USP44, corresponding to a region within the internal amino acids.
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- WB 1:500-1:1000, IF/ICC 1:100-1:500, ELISA(peptide) 1:20000-1:40000
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 mg/mL
-
Buffer
- Rabbit IgG in phosphate buffered saline , pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20 °C. Stable for 12 months from date of receipt.
-
Haltbarkeit
- 12 months
-
-
- USP44 (Ubiquitin Specific Peptidase 44 (USP44))
-
Andere Bezeichnung
- USP44
-
Hintergrund
-
Description: Deubiquitinase that plays a key regulatory role in the spindle assembly checkpoint or mitotic checkpoint by preventing premature anaphase onset. Acts by specifically mediating deubiquitination of CDC20, a negative regulator of the anaphase promoting complex/cyclosome (APC/C). Deubiquitination of CDC20 leads to stabilize the MAD2L1-CDC20-APC/C ternary complex (also named mitotic checkpoint complex), thereby preventing premature activation of the APC/C. Promotes association of MAD2L1 with CDC20 and reinforces the spindle assembly checkpoint. Acts as a negative regulator of histone H2B (H2BK120ub1) ubiquitination.
Gene: USP44
-
Molekulargewicht
- 81 kDa
-
Gen-ID
- 84101
-
UniProt
- Q9H0E7
-
Pathways
- M Phase
Target
-